Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 1;28(2):111937.
doi: 10.1016/j.isci.2025.111937. eCollection 2025 Feb 21.

NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection

Affiliations

NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection

Nadine Hundhausen et al. iScience. .

Abstract

NFAT is a family of transcription factors whose activation is inhibited by calcineurin inhibitors (CNIs). In allogeneic hematopoietic stem cell transplantation (allo-HCT), CNIs are employed to prevent and treat graft-versus-host disease (GvHD). Unfortunately, control of cytomegalovirus (CMV), which exacerbates clinical outcomes, is simultaneously lost. Since single NFAT deficiency in T cells ameliorates GvHD in our major mismatch model, we investigated whether protection is maintained during CMV infection. Reassuringly, NFAT-deficient T cells still improved GvHD upon acute CMV infection and after allo-HCT in latently CMV-infected mice, showing reduced proinflammatory and cytotoxic potential. In sharp contrast, CMV-specific NFAT-deficient CD8+ inflated memory T cells expanded more and with higher levels of interferon gamma (IFN-γ) and GzmB expression, effectively controlling CMV. Notably, NFAT-deficient inflated memory T cells could migrate to non-lymphoid tissues and fight CMV. Therefore, CMV infection does not interfere with the protective effect of NFAT inhibition to attenuate GvHD while allowing an anti-CMV response.

Keywords: Biological sciences; Immunology; Microbiology; Natural sciences; Virology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Co-transfer of single-deficient NFATc1 and NFATc2 or double-deficient NFATc1c2 T cells in a haploidentical major mismatch model limits signs of aGvHD even after an acute MCMV infection (A) Experimental in vivo set up of the induction of aGvHD in a haploidentical mouse model due to an H-2b → H-2b+d transfer with WT or NFAT-deficient T cells along with BM, preceded by lethal irradiation (9 Gy) of CB6F1 recipients. Two days post-transplantation, mice were acutely infected with 1 × 106 PFU of WT-MCMV Smith strain. Six or twelve days post-infection, ex vivo analyses were conducted on spleen, peripheral lymph nodes (pLNs), mesenteric lymph nodes (mLNs), salivary gland (SG), lungs, and liver. (B) Weight changes were determined over 14 days post-irradiation (dpi) in mice without (aGvHD) or with an acute MCMV infection (aGvHD + acute MCMV). Mice were evaluated every day and weight loss was calculated considering day 0 weight as 100%; n ≥ 5. (C) Clinical scores were determined over 14 days. (B and C) Two-way ANOVA and Tukey’s multiple comparisons test (∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 5, two independent experiments. (D) Virus DNA concentration of acutely infected mice 14 dpi in indicated organs was determined by RT-PCR. (E) Survival over 14 days.
Figure 2
Figure 2
NFAT-deficient T cells can still provide protection when transferred into latently infected recipients (A) Experimental in vivo set up. Latent infected CB6F1 recipient (90 days prior transplantation) with WT-MCMV Smith strain. Acute GvHD was initiated by transferring H-2b donor T cells together with BM cells into H-2b+d recipients, preceded by lethal irradiation (9 Gy) of CB6F1 recipients. Six or thirty days post-transplantation, ex vivo analyses were conducted on various tissues. Symbols representing studied genotypes in only aGVHD (D−/R−) and latently infected CB6F1 recipients (D−/R+). (B) Weight loss and (C) clinical scores of GvHD-induced mice in latently infected recipients were monitored daily for short (6 dpi) or long term (30 dpi). Two-way ANOVA and Tukey’s multiple comparisons test (∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 5, two independent experiments. (D) Virus DNA concentration 30 dpi, determined by RT-PCR, mean ± SD, n = 3, unpaired Student’s t test (∗p < 0.05, ∗∗p < 0.005). (E) Survival was monitored daily for 30 days.
Figure 3
Figure 3
Independent from MCMV infection, NFAT-deficient Tregs are significantly enriched during GvHD (A) Frequency and absolute cell numbers—calculated back to all cells of the particular organ—of donor CD90.1+CD4+CD25+Foxp3+ T cells 8 days post-transplantation in non-infected or acutely infected (MCMV+) recipients (spleen, pLN, mLN, salivary gland [SG], lungs, and liver). Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 4, three independent experiments. (B) Flow cytometric analyses of indicated organs harvested 6 days post-transplantation from mice without or with latent MCMV infection (R+). Percentage of CD25+Foxp3+ Tregs within donor CD90.1+CD4+ T cells and absolute cell numbers. (A and B) Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 3, two independent experiments.
Figure 4
Figure 4
The reduction of proinflammatory cytokines and cytotoxic molecules in NFAT-deficient CD8+ T cells during aGvHD remains significant regardless of a concurrent MCMV infection (A and B) Flow cytometric analyses of recipient mice without (R−) and with latent MCMV infection (R+) were conducted 6 days post-transplantation. (A) Frequency of donor CD90.1+CD8+IFN-γ+ T cells in the depicted organs, n ≥ 3. (B) Frequency of donor CD90.1+CD8+GzmB+ T cells. (A and B) Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 3, two independent experiments.
Figure 5
Figure 5
NFAT deficiency reduces CD8+ T cell exhaustion while promoting terminal differentiation of MCMV-specific CD8+ T cells after allo-HCT (A) Percentage of PD-1hiTOXhi in CD8+ T cells in only aGVHD and latently infected CB6F1 recipients (+MCMV) 6 days post-transplantation, n ≥ 3. (B) Percentages of the chemokine receptor CX3CR1+ and (C) type II transmembrane protein receptor KLRG1+ within MCMV-specific donor CD90.1+CD8+M38+ T cells was determined through tetramer staining and subsequent flow cytometry analysis. Fold change was calculated relative to WT. (A, B and C) Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n ≥ 3, two independent experiments.
Figure 6
Figure 6
NFAT deficiency in CD8+ T cells is sufficient to increase the frequency of IFN-γ+ MI T cells (A–C) Flow cytometric analyses of allotransplanted WT CD4+ T cells and WT or NFAT-deficient CD8+ T cells (1:1 ratio) 6 days post-transplantation. (A) Absolute numbers and (B) fold change of the percentage of KLRG1+ within MCMV-specific donor CD90.1+CD8+CD44+CD27M38+ T cells was determined through tetramer staining and subsequent flow cytometry analysis. Fold change was calculated specifically on WT. (C) Frequency of IFN-γ+ within MCMV-specific donor CD90.1+CD8+CD44+CD27M38+ T cells (in vitro restimulated). (A, B and C) Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.005, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n = 5.
Figure 7
Figure 7
After allo-HCT in latently MCMV-infected mice, NFAT-deficient MI T cells present with a higher frequency of IFN-γ+ and GzmB+ cells Percentage of (A) IFN-γ+ and (B) GzmB+ cells of either M38 or MCMV-specific M38+, M38+KLRG1+, and M38+KLRG1+CX3CR1+ CD8+ T cells after 6 days post-transplantation and in vitro restimulation. (A and B) Student’s two-tailed t test (∗p < 0.05, ∗∗p < 0.0051, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001), mean ± SEM, n = 3.

Similar articles

References

    1. Ferrara J.L.M., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–1561. - PMC - PubMed
    1. Zeiser R., Blazar B.R. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N. Engl. J. Med. 2017;377:2167–2179. doi: 10.1056/NEJMra1609337. - DOI - PMC - PubMed
    1. Vaeth M., Bäuerlein C.A., Pusch T., Findeis J., Chopra M., Mottok A., Rosenwald A., Beilhack A., Berberich-Siebelt F. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity. Proc. Natl. Acad. Sci. USA. 2015;112:1125–1130. doi: 10.1073/pnas.1409290112. - DOI - PMC - PubMed
    1. Vaeth M., Feske S. NFAT control of immune function: New Frontiers for an Abiding Trooper. F1000Res. 2018;7:260. doi: 10.12688/f1000research.13426.1. - DOI - PMC - PubMed
    1. Vaeth M., Schliesser U., Müller G., Reissig S., Satoh K., Tuettenberg A., Jonuleit H., Waisman A., Müller M.R., Serfling E., et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA. 2012;109:16258–16263. doi: 10.1073/pnas.1203870109. - DOI - PMC - PubMed

LinkOut - more resources